Patents Assigned to Shandong Luye Pharmaceutical Co., Ltd.
-
Patent number: 11110094Abstract: A risperidone sustained release microsphere formulation is provided. The microsphere formulation comprise risperidone or 9-hydroxy risperidone or salts thereof, and a polymer blend having a first uncapped lactide-glycolide copolymer and a second uncapped lactide-glycolide copolymer, in which the first uncapped lactide-glycolide copolymer is a copolymer with a high intrinsic viscosity and the second uncapped lactide-glycolide copolymer is a copolymer with a low intrinsic viscosity. The sustained release microsphere formulation according to an embodiment of the present disclosure is suitable for large-scale industrialized production with improved stability, the in vivo release behavior of which will not change after long-term storage.Type: GrantFiled: July 29, 2019Date of Patent: September 7, 2021Assignees: Shandong Luye Pharmaceutical Co., Ltd., Nanjing Luye Pharmaceutical Co., Ltd.Inventors: Kaoxiang Sun, Rongcai Liang, Oilin Wang, Wenyan Wang, Wanhui Liu, Youxin Li
-
Patent number: 11111227Abstract: The present disclosure relates to rotigotine behenate, methods for preparing the same and use of the same for treating diseases associated with dopamine receptor. The rotigotine behenate, the structure of which is shown below, is capable of reducing fluctuation in blood drug concentrations, improving the bioavailability of the drug in vivo, and achieving smooth and extended release of rotigotine.Type: GrantFiled: April 27, 2020Date of Patent: September 7, 2021Assignee: Shandong Luye Pharmaceutical Co., Ltd.Inventors: Mina Yang, Yongtao Jiang, Ying Meng, Tao Wang, Qian qian Xu, Xin Shao, Chunjie Sha
-
Patent number: 10669249Abstract: The present disclosure relates to rotigotine behenate, methods for preparing the same and use of the same for treating diseases associated with dopamine receptor. The rotigotine behenate, the structure of which is shown below, is capable of reducing fluctuation in blood drug concentrations, improving the bioavailability of the drug in vivo, and achieving smooth and extended release of rotigotine.Type: GrantFiled: July 21, 2016Date of Patent: June 2, 2020Assignee: Shandong Luye Pharmaceutical Co., Ltd.Inventors: Mina Yang, Yongtao Jiang, Ying Meng, Tao Wang, Qian qian Xu, Xin Shao, Chunjie Sha
-
Patent number: 10406161Abstract: A risperidone sustained release microsphere formulation is provided. The microsphere formulation comprise risperidone or 9-hydroxy risperidone or salts thereof, and a polymer blend having a first uncapped lactide-glycolide copolymer and a second uncapped lactide-glycolide copolymer, in which the first uncapped lactide-glycolide copolymer is a copolymer with a high intrinsic viscosity and the second uncapped lactide-glycolide copolymer is a copolymer with a low intrinsic viscosity. The sustained release microsphere formulation according to an embodiment of the present disclosure is suitable for large-scale industrialized production with improved stability, the in vivo release behavior of which will not change after long-term storage.Type: GrantFiled: September 27, 2018Date of Patent: September 10, 2019Assignees: SHANDONG LUYE PHARMACEUTICAL CO., LTD., NANJING LUYE PHARMACEUTICAL CO., LTD.Inventors: Kaoxiang Sun, Rongcai Liang, Qilin Wang, Wenyan Wang, Wanhui Liu, Youxin Li
-
Patent number: 10258572Abstract: A composition of goserelin sustained release microspheres is provided. The microspheres comprise goserelin, at least one poly (lactide-co-glycolide) and poloxamer or PEG. The sustained release microspheres have comparatively high bioavailability, which promotes the drug taking its full effect and have entrapment efficiency over 90%.Type: GrantFiled: October 20, 2017Date of Patent: April 16, 2019Assignee: Shandong Luye Pharmaceutical Co., Ltd.Inventors: Wei Sun, Xuemei Zhang, Tao Wang, Guangyi Leng, Kaoxiang Sun, Youxin Li, Wanhui Liu
-
Patent number: 10098882Abstract: A risperidone sustained release microsphere formulation is provided. The microsphere formulation includes risperidone or 9-hydroxy risperidone or salts thereof, and a polymer blend having a first uncapped lactide-glycolide copolymer and a second uncapped lactide-glycolide copolymer, in which the first uncapped lactide-glycolide copolymer is a copolymer with a high intrinsic viscosity and the second uncapped lactide-glycolide copolymer is a copolymer with a low intrinsic viscosity. The sustained release micro sphere formulation according to an embodiment of the present disclosure is suitable for large-scale industrialized production with improved stability, the in vivo release behavior of which will not change after long-term storage.Type: GrantFiled: November 9, 2016Date of Patent: October 16, 2018Assignees: Shandong Luye Pharmaceutical Co., Ltd., Nanjing Luye Pharmaceutical Co., Ltd.Inventors: Kaoxiang Sun, Rongcai Liang, Qilin Wang, Wenyan Wang, Wanhui Liu, Youxin Li
-
Publication number: 20180117123Abstract: An exenatide-containing composition is in the form of microspheres, which are prepared by using exenatide acetate and polylactic-co-glycolic acid (PLGA) as raw materials, and the content of acetic acid in the prepared composition is lower than 0.01%. A method for preparing the exenatide-containing microspheres includes selecting a cleaning fluid of a proper external water phase and a proper amount to clean microspheres, and selecting a proper re-drying temperature to cure the microspheres after the microspheres are freeze-dried.Type: ApplicationFiled: November 5, 2017Publication date: May 3, 2018Applicant: SHANDONG LUYE PHARMACEUTICAL CO., LTD.Inventors: Tao Wang, Qilin Wang, Qianqian Xu, Lifang Sun, Ying Meng, Ju Li
-
Publication number: 20180036246Abstract: A composition of goserelin sustained release microspheres is provided. The microspheres comprise goserelin, at least one poly (lactide-co-glycolide) and poloxamer or PEG. The sustained release microspheres have comparatively high bioavailability, which promotes the drug taking its full effect and have entrapment efficiency over 90%.Type: ApplicationFiled: October 20, 2017Publication date: February 8, 2018Applicant: Shandong Luye Pharmaceutical Co., Ltd.Inventors: Wei Sun, Xuemei Zhang, Tao Wang, Guangyi Leng, Kaoxiang Sun, Youxin Li, Wanhui Liu
-
Publication number: 20170035856Abstract: An exenatide-containing composition is in the form of microspheres, which are prepared by using exenatide acetate and polylactic-co-glycolic acid (PLGA) as raw materials, and the content of acetic acid in the prepared composition is lower than 0.01%. A method for preparing the exenatide-containing microspheres includes selecting a cleaning fluid of a proper external water Phase and a proper amount to clean microspheres, and selecting a proper re-drying temperature to cure the after the microspheres are freeze dried.Type: ApplicationFiled: April 16, 2015Publication date: February 9, 2017Applicant: SHANDONG LUYE PHARMACEUTICAL CO., LTD.Inventors: Tao Wang, Qilin Wang, Qianqian Xu, Lifang Sun, Ying Meng, Ju Li
-
Patent number: 9532991Abstract: A risperidone sustained release microsphere formulation is provided. The microsphere formulation includes risperidone or 9-hydroxy risperidone or salts thereof, and a polymer blend having a first uncapped lactide-glycolide copolymer and a second uncapped lactide-glycolide copolymer, in which the first uncapped lactide-glycolide copolymer is a copolymer with a high intrinsic viscosity and the second uncapped lactide-glycolide copolymer is a copolymer with a low intrinsic viscosity. The sustained release micro sphere formulation according to an embodiment of the present disclosure is suitable for large-scale industrialized production with improved stability, the in vivo release behavior of which will not change after long-term storage.Type: GrantFiled: July 22, 2016Date of Patent: January 3, 2017Assignees: Shandong Luye Pharmaceutical Co., Ltd., Nanjing Luye Pharmaceutical Co., LtdInventors: Kaoxiang Sun, Rongcai Liang, Qilin Wang, Wenyan Wang, Wanhui Liu, Youxin Li
-
Patent number: 9446135Abstract: A risperidone sustained release microsphere formulation is provided. The microsphere formulation comprise risperidone or 9-hydroxy risperidone or salts thereof, and a polymer blend having a first uncapped lactide-glycolide copolymer and a second uncapped lactide-glycolide copolymer, in which the first uncapped lactide-glycolide copolymer is a copolymer with a high intrinsic viscosity and the second uncapped lactide-glycolide copolymer is a copolymer with a low intrinsic viscosity. The sustained release micro sphere formulation according to an embodiment of the present disclosure is suitable for large-scale industrialized production with improved stability, the in vivo release behavior of which will not change after long-term storage.Type: GrantFiled: April 10, 2012Date of Patent: September 20, 2016Assignee: Shandong Luye Pharmaceutical Co., Ltd.Inventors: Kaoxiang Sun, Rongcai Liang, Qilin Wang, Wenyan Wang, Wanhui Liu, Youxin Li
-
Publication number: 20160022584Abstract: A composition of goserelin sustained release microspheres is provided. The microspheres comprise goserelin, at least one poly(lactide-co-glycolide) and poloxamer or PEG. The sustained release microspheres have comparatively high bioavailability, which promotes the drug taking its full effect and have entrapment efficiency over 90%.Type: ApplicationFiled: October 8, 2015Publication date: January 28, 2016Applicant: Shandong Luye Pharmaceutical Co., Ltd.Inventors: Wei Sun, Xuemei Zhang, Tao Wang, Guangyi Leng, Kaoxiang Sun, Youxin Li, Wanhui Liu
-
Patent number: 9220782Abstract: The present invention relates to a long-acting sustained-release dosage form for treatment of Parkinson Disease, comprising a dopamine receptor agonist and a pharmaceutically acceptable biodegradable polymer accessories, wherein the content of the dopamine receptor agonist in the sustained-release dosage form is 5-50% by weight, and the content of the pharmaceutically acceptable polymer accessories is 50-95% by weight.Type: GrantFiled: March 17, 2014Date of Patent: December 29, 2015Assignee: Shandong Luye Pharmaceutical Co., Ltd.Inventor: Luping Zhang
-
Patent number: 9199912Abstract: The present disclosure relates to polymorphs of 4-[2-dimethylamino-1-(1-hydroxycyclohexyl)ethyl]phenyl 4-methylbenzoate hydrochloride, methods for preparing the same and use of the same.Type: GrantFiled: April 23, 2014Date of Patent: December 1, 2015Assignees: SHANDONG LUYE PHARMACEUTICAL CO., LTD.Inventors: Youxin Li, Wanhui Liu, Yang Lv, Guanhua Du, Qingguo Meng, Mina Yang, Fengmei Zhou, Ju Li, Xuemei Zhang
-
Patent number: 9012660Abstract: The present disclosure relates to 5,6,7,8-tetrahydro-6-[N,N-bis[(2-thienyl)ethyl]]amino-1-naphthol, a method for preparing the same, and use of 5,6,7,8-tetrahydro-6-[N,N-bis[(2-thienyl)ethyl]]amino-1-naphthol as a reference compound for determining an impurity in rotigotine or a preparation thereof.Type: GrantFiled: August 6, 2012Date of Patent: April 21, 2015Assignee: Shandong Luye Pharmaceutical Co., Ltd.Inventors: Mina Yang, Yanyan Zhao, Fengmei Zhou, Quingguo Meng, Tao Wang
-
Publication number: 20140255488Abstract: The present invention relates to a long-acting sustained-release dosage form for treatment of Parkinson Disease, comprising a dopamine receptor agonist and a pharmaceutically acceptable biodegradable polymer accessories, wherein the content of the dopamine receptor agonist in the sustained-release dosage form is 5-50% by weight, and the content of the pharmaceutically acceptable polymer accessories is 50-95% by weight.Type: ApplicationFiled: March 17, 2014Publication date: September 11, 2014Applicant: Shandong Luye Pharmaceutical Co., Ltd.Inventor: Luping Zhang
-
Publication number: 20140235728Abstract: The present disclosure relates to polymorphs of 4-[2-dimethylamino-1-(1-hydroxycyclohexyl)ethyl]phenyl 4-methylbenzoate hydrochloride, methods for preparing the same and use of the same.Type: ApplicationFiled: April 23, 2014Publication date: August 21, 2014Applicants: Shandong Luye Pharmaceutical Co., Ltd.Inventors: Youxin Li, Wanhui Liu, Yang Lv, Guanhua Du, Qingguo Meng, Mina Yang, Fengmei Zhou, Ju Li, Xuemei Zhang
-
Publication number: 20140196523Abstract: The present disclosure relates to 5,6,7,8-tetrahydro-6-[N,N-bis[(2-thienypethyl]]amino-1-naphthol, a method for preparing the same, and use of 5,6,7,8-tetrahydro-6-[N,N-bis[(2-thienypethyl]]amino-1-naphthol as a reference compound for determining an impurity in rotigotine or a preparation thereof.Type: ApplicationFiled: August 6, 2012Publication date: July 17, 2014Applicant: SHANDONG LUYE PHARMACEUTICAL CO., LTD.Inventors: Mina Yang, Yanyan Zhao, Fengmei Zhou, Quingguo Meng, Tao Wang
-
Patent number: 8691277Abstract: The present invention relates to a long-acting sustained-release dosage form for treatment of Parkinson Disease, comprising a dopamine receptor agonist and a pharmaceutically acceptable biodegradable polymer accessories, wherein the content of the dopamine receptor agonist in the sustained-release dosage form is 5-50% by weight, and the content of the pharmaceutically acceptable polymer accessories is 50-95% by weight.Type: GrantFiled: September 21, 2005Date of Patent: April 8, 2014Assignee: Shandong Luye Pharmaceutical Co., Ltd.Inventor: Luping Zhang
-
Publication number: 20140050799Abstract: A risperidone sustained release microsphere formulation is provided. The microsphere formulation comprise risperidone or 9-hydroxy risperidone or salts thereof, and a polymer blend having a first uncapped lactide-glycolide copolymer and a second uncapped lactide-glycolide copolymer, in which the first uncapped lactide-glycolide copolymer is a copolymer with a high intrinsic viscosity and the second uncapped lactide-glycolide copolymer is a copolymer with a low intrinsic viscosity. The sustained release micro sphere formulation according to an embodiment of the present disclosure is suitable for large-scale industrialized production with improved stability, the in vivo release behavior of which will not change after long-term storage.Type: ApplicationFiled: April 10, 2012Publication date: February 20, 2014Applicant: SHANDONG LUYE PHARMACEUTICAL CO., LTD.Inventors: Kaoxiang Sun, Rongcai Liang, Qilin Wang, Wenyan Wang, Wanhui Liu, Youxin Li